Hiv env proteins: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 35: | Line 35: | ||
== Other Research ==<StructureSection load='3dnn' size='400' side='right' caption='Molecular structure for the HIV-1 gp120 trimer in the unliganded state (PDB entry [[3dnn]])' scene=''> | == Other Research ==<StructureSection load='3dnn' size='400' side='right' caption='Molecular structure for the HIV-1 gp120 trimer in the unliganded state (PDB entry [[3dnn]])' scene=''> | ||
There is currently no cure or vaccine for HIV. Thus, there are constantly new studies being conducted, that explore various aspects of HIV. One recent study done at the University of Amsterdam, explored the evolution of HIV post-infection and discovered that HIV can evolve glycan structures that induce the production of broadly cross neutralizing (BCN) antibodies. | There is currently no cure or vaccine for HIV. Thus, there are constantly new studies being conducted, that explore various aspects of HIV. One recent study done at the University of Amsterdam, explored the evolution of HIV post-infection and discovered that HIV can evolve glycan structures that induce the production of broadly cross neutralizing (BCN) antibodies. "The role of glycans in shielding neutralizing epitopes has | ||
long been known but it has only recently become clear that many BCN responses directly target glycans, including the one that evolves at | |||
<scene name='Hiv_env_proteins/Asn_glycosylation/1'>position 332</scene> on the gp120 construct"<ref name=Nick>PMID: 23086475 </ref>. | |||
</StructureSection> | </StructureSection> | ||
